SubsidieMeestersDevelopment of the first oral disease-modifying treatment for chronic obstructive pulmonary disease (COPD)
Palobiofarma aims to develop PBF-680, a first-in-class adenosine receptor antagonist, to treat COPD, targeting disease progression and seeking €30M for further clinical trials.
Projectdetails
Introduction
Palobiofarma is a Spanish biotech company with the ambition to develop new treatments for cancer and autoimmune diseases based on adenosine receptor modulation.
Product Overview
Our compound PBF-680 is a first-in-class therapy with disease-modifying effects in respiratory diseases like COPD. Over 65 million patients suffer from COPD, yet there are no approved therapies that target disease progression.
Mechanism of Action
PBF-680 is a unique molecule designed to specifically antagonize the Adenosine 1 Receptor (A1R). It has shown to be safe and well-tolerated in phase 1 trials and demonstrated to reduce pulmonary symptoms and inflammation in mild-to-moderate asthmatics in phase 2 trials.
Funding and Future Plans
With funding from the EIC Accelerator, we will demonstrate efficacy in a phase 2 trial in COPD, a market with high unmet medical need.
Milestones and Financial Goals
Proven clinical efficacy will be the major milestone to raise €30 million (including €15 million EIC Equity) for a phase 3 trial, followed by an additional fundraising or IPO to independently reach market launch with PBF-680.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.476.106 |
| Totale projectbegroting | € 3.537.295 |
Tijdlijn
| Startdatum | 1-1-2022 |
| Einddatum | 30-6-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- PALO BIOFARMA SLpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
PN6047 - a breakthrough treatment of neuropathic painPharmNovo aims to advance PN6047, a selective delta opioid receptor agonist for neuropathic pain, through Phase IIa trials to confirm efficacy and attract investment for further development. | EIC Accelerator | € 2.493.000 | 2024 | Details |
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug developmentCherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing. | EIC Accelerator | € 2.499.831 | 2024 | Details |
A disruptive hypoxia activated prodrug for the treatment of resistant cancers: an AI-driven approachTUMAGOSTIC aims to advance CP-506, a targeted Hypoxia Activated Prodrug, through clinical trials to improve cancer treatment efficacy and patient outcomes, with commercialization potential exceeding €450M. | EIC Accelerator | € 2.462.533 | 2024 | Details |
APAC – the first targeted therapy for peripheral arterial occlusive disease.Aplagon is developing APAC, a targeted therapy for advanced peripheral arterial occlusive disease, aiming to improve safety and efficacy in clinical studies to address high morbidity and mortality rates. | EIC Accelerator | € 2.099.387 | 2022 | Details |
A breakthrough active immunotherapy for the treatment of osteoarthritisPeptinov aims to halt osteoarthritis progression through a cost-effective immunotherapy that neutralizes IL-6, with promising Phase I results leading to a Phase II trial for out-licensing readiness. | EIC Accelerator | € 2.499.999 | 2024 | Details |
PN6047 - a breakthrough treatment of neuropathic pain
PharmNovo aims to advance PN6047, a selective delta opioid receptor agonist for neuropathic pain, through Phase IIa trials to confirm efficacy and attract investment for further development.
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug development
Cherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing.
A disruptive hypoxia activated prodrug for the treatment of resistant cancers: an AI-driven approach
TUMAGOSTIC aims to advance CP-506, a targeted Hypoxia Activated Prodrug, through clinical trials to improve cancer treatment efficacy and patient outcomes, with commercialization potential exceeding €450M.
APAC – the first targeted therapy for peripheral arterial occlusive disease.
Aplagon is developing APAC, a targeted therapy for advanced peripheral arterial occlusive disease, aiming to improve safety and efficacy in clinical studies to address high morbidity and mortality rates.
A breakthrough active immunotherapy for the treatment of osteoarthritis
Peptinov aims to halt osteoarthritis progression through a cost-effective immunotherapy that neutralizes IL-6, with promising Phase I results leading to a Phase II trial for out-licensing readiness.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Clinical readiness of a live biotherapeutic for treatment of Non-Small Cell Lung Cancer (NSCLC)Pulmobiotics aims to develop PB_LC, an engineered Mycoplasma pneumoniae strain, to enhance immunotherapy for NSCLC patients by improving T cell infiltration and overcoming treatment resistance. | EIC Transition | € 1.881.875 | 2023 | Details |
Targeting OGG1 in Idiopathic Pulmonary FibrosisThe TOPFIBRO project aims to advance OXC-201, a novel IPF treatment, through efficacy validation, safety assessments, and regulatory preparations for first-in-human studies, targeting a market launch. | EIC Transition | € 2.499.998 | 2023 | Details |
Diagnostische beeldvorming van vroege longfibroseBiOrion ontwikkelt een haalbaarheidsplan voor het gebruik van PET-tracers bij longfibrose om investeerders te werven en de klinische ontwikkeling te financieren. | Mkb-innovati... | € 14.426 | 2022 | Details |
Preclinical development of new nucleoside-based drug against leukemiaThe project aims to develop Carbacitabin (CAB) as a stable, effective treatment for high-risk leukemia patients through preclinical optimization, safety studies, and commercial preparation. | ERC Proof of... | € 150.000 | 2024 | Details |
Novel macrodiolide ImmunosuppressantsThis project aims to develop novel macrocyclic immunosuppressants targeting IRF3 to address autoimmune and neuroinflammatory disorders, while securing IP and preparing for future investment. | ERC Proof of... | € 150.000 | 2025 | Details |
Clinical readiness of a live biotherapeutic for treatment of Non-Small Cell Lung Cancer (NSCLC)
Pulmobiotics aims to develop PB_LC, an engineered Mycoplasma pneumoniae strain, to enhance immunotherapy for NSCLC patients by improving T cell infiltration and overcoming treatment resistance.
Targeting OGG1 in Idiopathic Pulmonary Fibrosis
The TOPFIBRO project aims to advance OXC-201, a novel IPF treatment, through efficacy validation, safety assessments, and regulatory preparations for first-in-human studies, targeting a market launch.
Diagnostische beeldvorming van vroege longfibrose
BiOrion ontwikkelt een haalbaarheidsplan voor het gebruik van PET-tracers bij longfibrose om investeerders te werven en de klinische ontwikkeling te financieren.
Preclinical development of new nucleoside-based drug against leukemia
The project aims to develop Carbacitabin (CAB) as a stable, effective treatment for high-risk leukemia patients through preclinical optimization, safety studies, and commercial preparation.
Novel macrodiolide Immunosuppressants
This project aims to develop novel macrocyclic immunosuppressants targeting IRF3 to address autoimmune and neuroinflammatory disorders, while securing IP and preparing for future investment.